12:02 PM
 | 
Aug 30, 2018
 |  BioCentury  |  Finance

Building a deeper Harbour

How Harbour BioMed plans pipeline growth after GIC-led $85 million series B

With an $85 million B round in hand, Harbour BioMed plans to advance newly in-licensed clinical programs while simultaneously building its pipeline through its internal platform and co-discovery deals.

Singapore sovereign wealth fund GIC led the round, which closed on Aug. 27. Fellow new investors China Life Private Equity Investment Company and Vertex Ventures and existing investors AdvanTech and Legend Capital also participated.

Harbour has historically out-licensed its transgenic mouse platforms as well as rights to antibodies discovered through the platforms. In the past year, the company has granted companies including...

Read the full 435 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >